[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2024011494A - Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para su uso en el tratamiento de trastornos del snc. - Google Patents

Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para su uso en el tratamiento de trastornos del snc.

Info

Publication number
MX2024011494A
MX2024011494A MX2024011494A MX2024011494A MX2024011494A MX 2024011494 A MX2024011494 A MX 2024011494A MX 2024011494 A MX2024011494 A MX 2024011494A MX 2024011494 A MX2024011494 A MX 2024011494A MX 2024011494 A MX2024011494 A MX 2024011494A
Authority
MX
Mexico
Prior art keywords
sup
treatment
cyclic group
cns disorders
neuroactive steroids
Prior art date
Application number
MX2024011494A
Other languages
English (en)
Inventor
Francesco G Salituro
Maria Jesus Blanco-Pillado
Marshall Lee Morningstar
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2024011494A publication Critical patent/MX2024011494A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se provee un compuesto de Fórmula (I) (ver Fórmula) (I) o una sal farmacéuticamente aceptable de este, en donde n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a y R16b se definen en la presente. Asimismo, en la presente se proveen composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) y métodos para usar de los compuestos, por ejemplo, en el tratamiento de trastornos relacionados con el SNC.
MX2024011494A 2018-10-12 2021-04-09 Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para su uso en el tratamiento de trastornos del snc. MX2024011494A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862745109P 2018-10-12 2018-10-12

Publications (1)

Publication Number Publication Date
MX2024011494A true MX2024011494A (es) 2024-09-26

Family

ID=68425315

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021004159A MX2021004159A (es) 2018-10-12 2019-10-11 Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc.
MX2024011494A MX2024011494A (es) 2018-10-12 2021-04-09 Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para su uso en el tratamiento de trastornos del snc.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021004159A MX2021004159A (es) 2018-10-12 2019-10-11 Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc.

Country Status (14)

Country Link
US (1) US11634453B2 (es)
EP (2) EP3864022B1 (es)
JP (2) JP2022504607A (es)
CN (1) CN113166193A (es)
AR (1) AR116695A1 (es)
AU (1) AU2019357040A1 (es)
BR (1) BR112021009428A2 (es)
CA (1) CA3115805A1 (es)
DK (1) DK3864022T3 (es)
ES (1) ES2966055T3 (es)
IL (1) IL282183A (es)
MX (2) MX2021004159A (es)
TW (1) TWI835884B (es)
WO (1) WO2020077255A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298436B2 (en) 2012-01-23 2024-07-01 Sage Therapeutics Inc Pharmaceutical preparations that include allopregnanolone
IL304912A (en) 2012-08-21 2023-10-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
CN115974956A (zh) 2016-08-23 2023-04-18 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
WO2019113494A1 (en) 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
ATE375993T1 (de) * 1994-02-14 2007-11-15 Euro Celtique Sa Androstane und pregane zur allosterischen modulation des gaba rezeptors
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
UA48154C2 (uk) 1994-11-23 2002-08-15 Косенсіз Інк. СПОЛУКИ РЯДУ АНДРОСТАНІВ ТА ПРЕГНАНІВ ДЛЯ АЛОСТЕРИЧНОЇ МОДУЛЯЦІЇ РЕЦЕПТОРА <font face="Symbol">g</font>-АМІНОМАСЛЯНОЇ КИСЛОТИ
PL2935307T3 (pl) 2012-12-18 2018-09-28 Washington University Neuroaktywne 19-alkoksy-17-podstawione steroidy, ich proleki oraz sposoby leczenia nimi
MX2021004492A (es) * 2014-10-16 2022-12-05 Sage Therapeutics Inc Composiciones para el tratamiento de trastornos del snc.
CN118085004A (zh) 2017-12-22 2024-05-28 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
BR112020012712A8 (pt) 2017-12-22 2022-03-03 Sage Therapeutics Inc Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc
CA3144701A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
BR112021026445A2 (pt) 2019-06-27 2022-03-08 Sage Therapeutics Inc Composições e métodos para tratar distúrbios de cns
AR121609A1 (es) 2020-03-18 2022-06-22 Sage Therapeutics Inc Esteroides neuroactivos y sus métodos de uso
AU2021296846A1 (en) 2020-06-24 2022-12-15 Sage Therapeutics, Inc. 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof

Also Published As

Publication number Publication date
WO2020077255A1 (en) 2020-04-16
JP2024040444A (ja) 2024-03-25
US20240051987A1 (en) 2024-02-15
MX2021004159A (es) 2021-09-08
EP4321519A2 (en) 2024-02-14
US11634453B2 (en) 2023-04-25
DK3864022T3 (da) 2023-12-18
CN113166193A (zh) 2021-07-23
US20210340172A1 (en) 2021-11-04
AR116695A1 (es) 2021-06-02
TWI835884B (zh) 2024-03-21
TW202027753A (zh) 2020-08-01
EP4321519A3 (en) 2024-05-01
EP3864022A1 (en) 2021-08-18
AU2019357040A1 (en) 2021-05-20
ES2966055T3 (es) 2024-04-18
CA3115805A1 (en) 2020-04-16
BR112021009428A2 (pt) 2021-08-31
JP2022504607A (ja) 2022-01-13
IL282183A (en) 2021-05-31
EP3864022B1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
MX2024011494A (es) Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para su uso en el tratamiento de trastornos del snc.
MX2024009540A (es) Esteroides neuroactivos y composiciones de estos.
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2023009611A (es) Esteroides neuroactivos, y su metodo de uso.
MX2024004788A (es) Esteroides neuroactivos y sus metodos de uso.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2021007504A (es) Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
MX2021007258A (es) Composiciones de esparsentan amorfas.
ZA202006071B (en) Antiproliferation compounds and uses thereof
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2022005650A (es) Agente terapeutico y agente profilactico para trastornos gastrointestinales funcionales y xerostomia.